EUVIMEDEUVIMED entdecken
Open Access

Orientation-dependent CD45 inhibition with viral and engineered ligands

Marta T Borowska iD, Liu D Liu iD, Nathanael A Caveney iD, Kevin M Jude iD, Won-Ju Kim, Takeya Masubuchi iD, Enfu Hui iD, Robbie G Majzner iD, K Christopher Garcia

Science Immunology · 2024

DOI: 10.1126/sciimmunol.adp0707 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, 2024. Verfasst von Marta T Borowska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94063, USA. Hauptthemen laut MEDLINE: Leukocyte Common Antigens. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, Howard Hughes Medical Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD45 is a cell surface phosphatase that shapes the T cell receptor signaling threshold but does not have a known ligand. A family of adenovirus proteins, including E3/49K, exploits CD45 to evade immunity by binding to the extracellular domain of CD45, resulting in the suppression of T cell signaling. We determined the cryo-EM structure of this complex and found that the E3/49K protein is composed of three immunoglobulin domains assembled as “beads on a string” that compel CD45 into a closely abutted dimer by cross-linking the CD45 D3 domain, leading to steric inhibition of its intracellular phosphatase activity. Inspired by the E3/49K mechanism, we engineered CD45 surrogate ligands that can fine-tune T cell activation by dimerizing CD45 into different orientations and proximities. The adenovirus E3/49K protein has taught us that, despite a lack of a known ligand, CD45 activity can be modulated by extracellular dimerizing ligands that perturb its phosphatase activity and alter T cell responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukocyte Common AntigensHumansLigandsT-LymphocytesViral ProteinsAdenoviridaeLymphocyte ActivationHEK293 CellsCryoelectron Microscopy

Substanzen

Leukocyte Common AntigensLigandsPTPRC protein, humanViral Proteins

Autor:innen und Institutionen

  • Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94063, USA.
  • Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94063, USA.
  • Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
  • Section of Cell and Developmental Biology, Division of Biological Sciences, University of California, San Diego, La Jolla, CA 92093, USA.
  • Department of Structural Biology, Stanford University, Stanford, CA 94063, USA.

ORCID-Profile: Marta T Borowska, Liu D Liu, Nathanael A Caveney, Kevin M Jude, Takeya Masubuchi, Enfu Hui, Robbie G Majzner

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • Howard Hughes Medical Institute

Zitieren

APA

Borowska, M. T., Liu, L. D., Caveney, N. A., Jude, K. M., Kim, W. J., Masubuchi, T., Hui, E., Majzner, R. G., & Garcia, K. C. (2024). Orientation-dependent CD45 inhibition with viral and engineered ligands. Science Immunology. https://doi.org/10.1126/sciimmunol.adp0707

Vancouver

Borowska MT, Liu LD, Caveney NA, Jude KM, Kim WJ, Masubuchi T, et al. Orientation-dependent CD45 inhibition with viral and engineered ligands. Science Immunology. 2024. doi:10.1126/sciimmunol.adp0707

BibTeX
@article{Borowska2024,
  author = {Borowska, Marta T and Liu, Liu D and Caveney, Nathanael A and Jude, Kevin M and Kim, Won-Ju and Masubuchi, Takeya and Hui, Enfu and Majzner, Robbie G and Garcia, K Christopher},
  title = {Orientation-dependent CD45 inhibition with viral and engineered ligands},
  journal = {Science Immunology},
  year = {2024},
  doi = {10.1126/sciimmunol.adp0707}
}
Kostenlos starten →